Eisai Plans to Continue Eritoran (E5564) Phase III Severe Sepsis Trial, Based on Interim Analysis That Evaluated Efficacy and Safety Data

LONDON, March 26, 2010 – Eisai Europe Ltd. announced today that the Phase III ACCESS (A Controlled
Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of
the investigational compound eritoran (E5564) will continue enrolling to the
planned 2,000 patients. As part of a planned interim analysis, an independent
Data Monitoring Committee (DMC) has evaluated efficacy [...]

Shire Presents Positive Data for Patients With Type 1 Gaucher Disease Who Switched to VPRIV(TM)

Also Reported are Results of Retrospective Analysis of Phase I/II Study, Showing Success in Reaching Therapeutic Goals within 4 Years of Initiation of Treatment

CAMBRIDGE, Massachusetts, March 25, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today presented positive data from a Phase III
clinical trial (TKT-034) designed to evaluate the safety [...]